Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TYMS | P04818 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30430643 | 0.80 | CA1 (0.34) | MAOAMAOBKDM4EALDH1A1TYMS | |
| SCHEMBL13151641 | 0.78 | MAOA (0.32) | MAOAMAOBKDM4EALDH1A1TYMS | |
| Hydrochloric Acid SCHEMBL583867 | 0.76 | MAOA (0.31) | MAOAMAOBKDM4EALDH1A1TYMS | |
| SCHEMBL28494219 | 0.76 | CA1 (0.34) | MAOAMAOBKDM4EALDH1A1TYMS | |
| SCHEMBL855947 | 0.75 | MAOB (0.47) | MAOAMAOBKDM4EALDH1A1TYMS | |
| SCHEMBL854978 | 0.75 | MAOA (0.47) | MAOAMAOBKDM4EALDH1A1TYMS | |
| SCHEMBL32672790 | 0.75 | TDP2 (0.50) | MAOAMAOBKDM4EALDH1A1TYMS | |
| SCHEMBL31616856 | 0.75 | KDM4E (0.47) | MAOAMAOBKDM4EALDH1A1TYMS | |
| SCHEMBL4455687 | 0.75 | KDM4E (0.47) | MAOAMAOBKDM4EALDH1A1TYMS | |
| SCHEMBL1611599 | 0.75 | MAOA (0.47) | MAOAMAOBKDM4EALDH1A1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2026-03-26 | — | — | US | disclosed |
| US-12331029-B2 | Orexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-06-17 | — | — | US | disclosed |
| WO-2020120994-A1 | OREXIN 1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-18 | — | — | WO | disclosed |
| CN-105849094-A | Method for producing halogen-substituted phthalide | 住友化学株式会社 | 2016-08-10 | — | — | CN | disclosed |
| US-8604221-B2 | Production method of halogen-substituted phthalide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20120142946-A1 | PRODUCTION METHOD OF HALOGEN-SUBSTITUTED PHTHALIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2433933-A1 | PRODUCTION METHOD OF HALOGEN-SUBSTITUTED PHTHALIDE | Sumitomo Chemical Company, Limited (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | CNR1, CNR2, OPRM1 | MAOA 133/4885MAOB 118/4885KDM4E 1401/4885 |
| US-12331029-B2 | Orexin 1 receptor antagonists | HCRTR1, HCRTR2, NPY1R | MAOA 385/4885MAOB 370/4885KDM4E 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.